{"id":510253,"date":"2021-07-07T08:24:51","date_gmt":"2021-07-07T12:24:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/"},"modified":"2021-07-07T08:24:51","modified_gmt":"2021-07-07T12:24:51","slug":"ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/","title":{"rendered":"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, July 7, 2021<\/span> \/PRNewswire\/ — Johnson Fistel<\/span>, LLP is investigating potential claims on behalf of ChemoCentryx Inc. (“ChemoCentryx” or the “Company”) (NASDAQ:<\/span>\u00a0CCXI)\u00a0against certain of its current and former officers and directors.\u00a0<\/p>\n

Recently a class action lawsuit was filed in federal court against the Company on behalf of purchasers of the securities of ChemoCentryx\u00a0from November 26, 2019<\/span> and May 6<\/span>, 2021\u00a0(the “Class Period”). <\/p>\n

The Complaint alleges that the Company failed to disclose to investors that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s NDA for avacopan for the treatment of ANCA associated vasculitis; and (4) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.<\/p>\n

\n
\n If you are a current, long-term shareholder of <\/u>
\n <\/b>
\n
\n ChemoCentryx<\/u>
\n <\/b>
\n
\n , holding shares before <\/u>
\n <\/b>
\n
\n
\n November 26, 2019<\/span>
\n <\/u>
\n <\/b>, you may have standing to hold ChemoCentryx\u00a0harmless from the alleged harm caused by the officers and directors of the Company by making them personally responsible. You may also be able to assist in reforming the Company’s corporate governance to prevent future wrongdoing.\u00a0<\/p>\n

\n If you<\/b>\u00a0are interested in learning more about the investigation, please contact <\/b>lead analyst <\/b>Jim Baker<\/span> (jimb@johnsonfistel.com<\/a>) at 619-814-4471. If emailing, please include a phone number.<\/b>\u00a0<\/p>\n

\n Additionally, if you are a current, long-term shareholder of <\/b>
\n ChemoCentryx<\/b>
\n , holding shares before <\/b>
\n
\n November 26, 2019<\/span>
\n <\/b>, you can<\/b> [Click here to join this action<\/a><\/b>]. There is no cost or obligation to you.<\/p>\n

About Johnson Fistel<\/span>, LLP:
Johnson Fistel<\/span>, LLP is a nationally recognized shareholder rights law firm with offices in California<\/span>, New York<\/span> and Georgia<\/span>. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http:\/\/www.johnsonfistel.com<\/a>. Attorney advertising. Past results do not guarantee future outcomes.<\/p>\n

Contact:
Johnson Fistel<\/span>, LLP
Jim Baker<\/span>, 619-814-4471
jimb@johnsonfistel.com<\/a><\/b><\/p>\n

[Click here to join this action<\/a><\/b>]<\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses-301326920.html<\/a><\/p>\n

SOURCE Johnson Fistel<\/span>, LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO, July 7, 2021 \/PRNewswire\/ — Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. (“ChemoCentryx” or the “Company”) (NASDAQ:\u00a0CCXI)\u00a0against certain of its current and former officers and directors.\u00a0 Recently a class action lawsuit was filed in federal court against the Company on behalf of purchasers of the securities of ChemoCentryx\u00a0from November 26, 2019 and May 6, 2021\u00a0(the “Class Period”). The Complaint alleges that the Company failed to disclose to investors that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase … <\/p>\n

Continue reading “(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510253","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\n(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses? - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses? - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, July 7, 2021 \/PRNewswire\/ — Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. (“ChemoCentryx” or the “Company”) (NASDAQ:\u00a0CCXI)\u00a0against certain of its current and former officers and directors.\u00a0 Recently a class action lawsuit was filed in federal court against the Company on behalf of purchasers of the securities of ChemoCentryx\u00a0from November 26, 2019 and May 6, 2021\u00a0(the “Class Period”). The Complaint alleges that the Company failed to disclose to investors that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase … Continue reading "(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T12:24:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH34977&sd=2021-07-07\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?\",\"datePublished\":\"2021-07-07T12:24:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/\"},\"wordCount\":393,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH34977&sd=2021-07-07\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/\",\"name\":\"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses? - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH34977&sd=2021-07-07\",\"datePublished\":\"2021-07-07T12:24:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH34977&sd=2021-07-07\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH34977&sd=2021-07-07\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses? - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/","og_locale":"en_US","og_type":"article","og_title":"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses? - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, July 7, 2021 \/PRNewswire\/ — Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. (“ChemoCentryx” or the “Company”) (NASDAQ:\u00a0CCXI)\u00a0against certain of its current and former officers and directors.\u00a0 Recently a class action lawsuit was filed in federal court against the Company on behalf of purchasers of the securities of ChemoCentryx\u00a0from November 26, 2019 and May 6, 2021\u00a0(the “Class Period”). The Complaint alleges that the Company failed to disclose to investors that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase … Continue reading \"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T12:24:51+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH34977&sd=2021-07-07","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?","datePublished":"2021-07-07T12:24:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/"},"wordCount":393,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH34977&sd=2021-07-07","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/","name":"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses? - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH34977&sd=2021-07-07","datePublished":"2021-07-07T12:24:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH34977&sd=2021-07-07","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH34977&sd=2021-07-07"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510253"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510253\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}